BIOMARIN PHARMACEUTICAL INC (BMRN)
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.
Address
105 DIGITAL DRIVE
NOVATO, CA 94949
Founded
1997
Number of Employees
3,401
Website
http://www.biomarin.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | $50,000 | - | - | - | - | $50,000 |
| Average Price | - | - | - | - | - | - | $96.47 | - | - | - | - | $96.47 |
| # Shares Purchased | - | - | - | - | - | - | 518,296 | - | - | - | - | 518,296 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | -12.9% | - | - | - | - | -12.9% |
| S&P 500 Return to Date | - | - | - | - | - | - | 74.8% | - | - | - | - | 74.8% |
| Excess Total Return | - | - | - | - | - | - | -87.8% | - | - | - | - | -87.8% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | 22% | - | - | - | - | 33% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at BMRN make a trade.
Creating a free account takes less than one minute